Literature DB >> 33435173

Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.

Bohyun Kim1, Insoon Jang2, Kwangsoo Kim3, Minsun Jung1, Cheol Lee1, Jeong Hwan Park4, Young A Kim4, Kyung Chul Moon1,5.   

Abstract

A number of urinary bladder urothelial carcinoma (UB UC) mRNA-based classification systems have been reported. It also has been observed that treatment response and prognosis are different for each molecular subtype. In this study, cytokeratin (CK)5/6 and CK20 immunohistochemistry (IHC) were performed, and IHC-based subgroup classification was applied. UB UC was classified into CK5/6 single-positive (SP), CK20 SP, double-positive (DP) and double-negative (DN) subgroups, and transcriptional analysis was performed. The results of gene ontology (GO) terms and functional analysis using differentially expressed genes indicate that, CK5/6 SP and DP subgroups were enriched in cell migration, immune activation, interleukin 6-Janus kinase-signal transducer and activator of transcription 3 (IL6-JAK-STAT3) signaling pathway and tumor necrosis factor-α signaling via the nuclear factor-κB (NF-κB) signaling pathway signature gene. In addition, compared with the other subgroups, the DN subgroup showed inhibited cell movement, cell migration, and cell activation. Furthermore, in survival analysis, the CK5/6 SP subgroup was significantly associated with poor progression-free survival (p = 0.008). The results of our study indicate that the CK5/6 positive subgroup exhibited high gene expression signature related to aggressive behavior and exhibited worse clinical outcome.

Entities:  

Keywords:  cytokeratin 20; cytokeratin 5/6; molecular classification; muscle invasive bladder cancer

Mesh:

Substances:

Year:  2021        PMID: 33435173      PMCID: PMC7828072          DOI: 10.3390/ijms22020628

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  40 in total

1.  Prognostic significance of nuclear pSTAT3 in oral cancer.

Authors:  Muzafar A Macha; Ajay Matta; Jatinder Kaur; S S Chauhan; Alok Thakar; Nootan K Shukla; Siddhartha Datta Gupta; Ranju Ralhan
Journal:  Head Neck       Date:  2011-04       Impact factor: 3.147

Review 2.  Mechanisms of motility in metastasizing cells.

Authors:  Mahmut Yilmaz; Gerhard Christofori
Journal:  Mol Cancer Res       Date:  2010-05-11       Impact factor: 5.852

Review 3.  Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Andrea Ochoa; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney
Journal:  Hematol Oncol Clin North Am       Date:  2015-04       Impact factor: 3.722

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 5.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

6.  Toward a molecular pathologic classification of urothelial carcinoma.

Authors:  Gottfrid Sjödahl; Kristina Lövgren; Martin Lauss; Oliver Patschan; Sigurdur Gudjonsson; Gunilla Chebil; Mattias Aine; Pontus Eriksson; Wiking Månsson; David Lindgren; Mårten Fernö; Fredrik Liedberg; Mattias Höglund
Journal:  Am J Pathol       Date:  2013-07-01       Impact factor: 4.307

7.  A molecular taxonomy for urothelial carcinoma.

Authors:  Gottfrid Sjödahl; Martin Lauss; Kristina Lövgren; Gunilla Chebil; Sigurdur Gudjonsson; Srinivas Veerla; Oliver Patschan; Mattias Aine; Mårten Fernö; Markus Ringnér; Wiking Månsson; Fredrik Liedberg; David Lindgren; Mattias Höglund
Journal:  Clin Cancer Res       Date:  2012-05-02       Impact factor: 12.531

8.  Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.

Authors:  Jordan Kardos; Shengjie Chai; Lisle E Mose; Sara R Selitsky; Bhavani Krishnan; Ryoichi Saito; Michael D Iglesia; Matthew I Milowsky; Joel S Parker; William Y Kim; Benjamin G Vincent
Journal:  JCI Insight       Date:  2016-03-17

9.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

10.  Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Authors:  Seth P Lerner; David J McConkey; Katherine A Hoadley; Keith S Chan; William Y Kim; François Radvanyi; Mattias Höglund; Francisco X Real
Journal:  Bladder Cancer       Date:  2016-01-07
View more
  3 in total

Review 1.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Matteo Landriscina; Vincenza Conteduca; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

Review 2.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

Review 3.  Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma.

Authors:  Hui Xie; Felix K-H Chun; Jochen Rutz; Roman A Blaheta
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.